Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 1, 2012, Pages 70-78

  Beebe Dimmer, Jennifer L ^a,b   Cetin, Karynsa ^c   Shahinian, Vahakn ^d   Morgenstern, Hal ^e   Yee, Cecilia ^a   Schwartz, Kendra L ^a   Acquavella, John ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Epidemiology; GnRH agonist; Mortality; Orchiectomy; Prostate cancer; SEER Medicare; Skeletal related events

Indexed keywords

ANDROGEN; GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EXPOSURE; FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; UNITED STATES;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FRACTURES, BONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; MALE; MEDICARE; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84855345391     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2258     Document Type: Article

References (42)

1. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008 Jan; 5(1): 24-34.
2. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 Jan 13; 352(2): 154-164.
3. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005 Nov 1; 23(31): 7897-7903.
4. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 Sep 20; 24(27): 4448-4456.
5. Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol 2009 Nov 17. [Epub ahead of print].
6. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999 Apr; 161(4): 1219-1222.
7. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002 Aug; 87(8): 3656-3661.
8. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002 Jun; 167(6): 2361-2367.
9. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007 Mar 20; 146(6): 416-424.
10. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 Sep 27; 345(13): 948-955.
11. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003 Jun; 169(6): 2008-2012.
12. Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007 Mar; 5(4): 271-277.
13. Smith MR, Egerdie B, Hernandez TN, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009 Aug 20; 361(8): 745-755.
14. Vanderwalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 2011 May; 61(3): 139-156.
15. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006 Sep; 176(3): 972-978.
16. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006 Jan; 175(1): 136-139.
17. Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Incidence and risk factors for low trauma fractures in men with prostate cancer. Bone 2008 Sep; 43(3): 556-560.
18. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007 Oct; 100(4): 749-754.
19. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993 Aug; 31(8): 732-748.
20. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002 Aug; 40(8 Suppl): IV-35.
21. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 2002 Aug; 40(8 Suppl): IV-25.
22. McKnight B, Cook LS, Weiss NS. Logistic regression analysis for more than one characteristic of exposure. Am J Epidemiol 1999 Jun 1; 149(11): 984-992.
23. Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003 Jul; 9(7): 2394-2399.
24. Burr DB. Introduction--Bone turnover and fracture risk. J Musculoskelet Neuronal Interact 2003 Dec; 3(4): 408-409.
25. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004 Mar; 20(3): 341-349.
26. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999 Jul; 14(7): 1061-1066.
27. Riggs BL, Khosla S, Melton LJ, III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002 Jun; 23(3): 279-302.
28. Bolla M, de Reijke TM, Van TG, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009 Jun 11; 360(24): 2516-2527.
29. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004 Aug 18; 292(7): 821-827.
30. Abrahamsen B, van ST, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 2009 Oct; 20(10): 1633-1650.
31. Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010 Mar 16; 152(6): 380-390.
32. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009 Feb 4; 301(5): 513-521.
33. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 2002 Sep; 13(9): 731-737.
34. Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10(1): 73-78.
35. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002 Sep; 168(3): 1005-1007.
36. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009 Oct 14; 302(14): 1573-1579.
37. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008 Dec 15; 113(12): 3290-3297.
38. Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, et al. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010 Oct; 106(7): 979-985.
39. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010 Feb 16; 121(6): 833-840.
40. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999 Jun 1; 149(11): 981-983.
41. Berruti A, Dogliotti L, Bitossi R. Incidence of skeletal complications in patients with bone metastastic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers at baseline. J Urol 2000; 164: 1248-1253.
42. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002 Aug; 40(8 Suppl): IV-18.